Giovanni Barosi

TL;DR: These results, along with findings from COMFORT-I and the phase 1/2 study, suggest that ruxolitinib has the potential to alter the course of disease through a reduction in the burden of JAK2 V617F.

TL;DR: In this project, drug-specific recommendations targeting the use of new agents for multiple myeloma (MM) were produced using the GRADE system which separates the judgments on quality of evidence from the judgment about strength of recommendations.

TL;DR: It is demonstrated that primary myelofibrosis-derived megakaryocytes expressed increased levels of bioactive Transforming Growth Factor β1; however, higher levels of released Transforming growth factor did not lead to enhanced activation of downstream pathways.

TL;DR: Examination of TGFβ1 levels in Philadelphia-negative myeloproliferative diseases found that patients with primary myelofibrosis have higher peripheral blood plasma levels of both bioactive and total TGF β1 than healthy controls, with a balance bioactive/total T GFβ1 in favour of the latter.

TL;DR: This data indicates that once the BRCA1/BRCA2 gene is removed, the B cell reprograming strategy is likely to be a viable alternative to chemotherapy and may be helpful in the selection of patients for B-cell transplantation.